AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.39 USD
-0.05 (-2.05%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.38 -0.01 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for AC Immune falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 115 | 128 | 217 | 241 | 290 |
Receivables | 17 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 5 | 4 | 6 | 4 |
Total Current Assets | 139 | 134 | 222 | 247 | 295 |
Net Property & Equipment | 4 | 4 | 6 | 5 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 56 | 53 | 55 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 204 | 195 | 286 | 255 | 301 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 10 | 18 | 12 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 0 | 5 |
Total Current Liabilities | 15 | 12 | 22 | 15 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 3 | 8 | 8 | 8 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 18 | 32 | 25 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 1 |
Capital Surplus | 529 | 452 | 472 | 370 | 349 |
Retained Earnings | -352 | -277 | -220 | -142 | -76 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 179 | 177 | 254 | 230 | 274 |
Total Liabilities & Shareholder's Equity | 204 | 195 | 286 | 255 | 301 |
Total Common Equity | 179 | 177 | 254 | 230 | 274 |
Shares Outstanding | 84.40 | 83.50 | 72.60 | 71.70 | 67.50 |
Book Value Per Share | 2.12 | 2.12 | 3.50 | 3.21 | 4.06 |
Fiscal Year End for AC Immune falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 115 | 90 | 103 | 114 |
Receivables | NA | 17 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 7 | 7 | 6 |
Total Current Assets | NA | 139 | 98 | 110 | 121 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 56 | 57 | 56 | 54 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 204 | 162 | 174 | 183 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 11 | 10 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 15 | 13 | 12 | 12 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 20 | 19 | 18 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 529 | 492 | 482 | 466 |
Retained Earnings | NA | -352 | -351 | -329 | -303 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 179 | 142 | 155 | 165 |
Total Liabilities & Shareholder's Equity | NA | 204 | 162 | 174 | 183 |
Total Common Equity | 0 | 179 | 142 | 155 | 165 |
Shares Outstanding | 98.90 | 84.40 | 84.40 | 83.60 | 83.50 |
Book Value Per Share | 0.00 | 2.12 | 1.69 | 1.85 | 1.98 |